Deucravacitinib in the Treatment of Cicatricial Alopecias
Icahn School of Medicine at Mount Sinai
Summary
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants of any gender, age 18 years or older, at the time of informed consent at Screening * Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements. * Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and/or CHLG ≥3. * Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months. * A fema…
Interventions
- DrugDeucravacitinib
12mg once-daily oral treatment for 48 weeks.
Location
- Icahn School of Medicine at Mount SinaiNew York, New York